<DOC>
	<DOC>NCT00395135</DOC>
	<brief_summary>The purpose of this study is to assess the weight loss effect of lorcaserin at the end of the first year of treatment (Week 52) and to assess the ability of lorcaserin to maintain weight loss at the end of the second year of treatment (Week 104)</brief_summary>
	<brief_title>BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>Obese adults with a BMI 30 to 45 kg/m2 or overweight adults with a BMI 27 to 29.9 kg/m2 and at least one obesityrelated comorbidity (hypertension, dyslipidemia, cardiovascular disease, glucose intolerance, sleep apnea) Ability to complete a 2 year study Diabetes Pregnancy History of heart valve disease Serious or unstable current or past medical conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Weight loss</keyword>
	<keyword>lorcaserin</keyword>
	<keyword>APD356</keyword>
	<keyword>BLOOM</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Sleep apnea</keyword>
	<keyword>glucose tolerance</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>Arena</keyword>
</DOC>